Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
50
PMVP Quote, Financials, Valuation and Earnings
Last price:
$1.25
Seasonality move
:
-33.08%
Day range:
$1.23 - $1.28
52-week range:
$0.81 - $1.84
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.55x
Volume:
230.8K
Avg. volume:
267.8K
1-year change:
-17.33%
Market cap:
$66M
Revenue:
--
EPS (TTM):
-$1.58
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PMVP
PMV Pharmaceuticals, Inc.
|
-- | -$0.33 | -- | -8.56% | $7.60 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IGC
IGC Pharma, Inc.
|
$198K | -$0.02 | -24.9% | -15.25% | $3.88 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PBYI
Puma Biotechnology, Inc.
|
$49M | $0.04 | 16.12% | -41.13% | $3.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PMVP
PMV Pharmaceuticals, Inc.
|
$1.24 | $7.60 | $66M | -- | $0.00 | 0% | -- |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
CVM
CEL-SCI Corp.
|
$4.91 | $42.50 | $14.9M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma, Inc.
|
$0.30 | $3.88 | $27.9M | -- | $0.00 | 0% | 22.51x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.30 | $0.85 | $667.9M | 8.90x | $0.80 | 0% | 10.30x |
|
PBYI
Puma Biotechnology, Inc.
|
$5.63 | $3.50 | $283.7M | 7.60x | $0.00 | 0% | 1.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PMVP
PMV Pharmaceuticals, Inc.
|
0.76% | 1.993 | 1.25% | 10.50x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
CVM
CEL-SCI Corp.
|
58.65% | 1.679 | 143.38% | 0.32x |
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.805 | 0.39% | 0.78x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PBYI
Puma Biotechnology, Inc.
|
26.26% | 1.268 | 15.34% | 1.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PMVP
PMV Pharmaceuticals, Inc.
|
-$32K | -$22.5M | -50.85% | -51.97% | -- | -$19.8M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
CVM
CEL-SCI Corp.
|
-$959K | -$5.5M | -123.39% | -266.61% | -- | -$3.9M |
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PBYI
Puma Biotechnology, Inc.
|
$42.3M | $9.6M | 23.32% | 38.49% | 17.57% | $9.7M |
PMV Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns PMVP or AIM?
AIM ImmunoTech has a net margin of -- compared to PMV Pharmaceuticals, Inc.'s net margin of -10571.43%. PMV Pharmaceuticals, Inc.'s return on equity of -51.97% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital PMVPPMV Pharmaceuticals, Inc.-- -$0.40 $121.9M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About PMVP or AIM?
PMV Pharmaceuticals, Inc. has a consensus price target of $7.60, signalling upside risk potential of 512.9%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than PMV Pharmaceuticals, Inc., analysts believe AIM ImmunoTech is more attractive than PMV Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMVPPMV Pharmaceuticals, Inc.6 0 0 AIMAIM ImmunoTech1 0 0 -
Is PMVP or AIM More Risky?
PMV Pharmaceuticals, Inc. has a beta of 1.643, which suggesting that the stock is 64.283% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock PMVP or AIM?
PMV Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PMV Pharmaceuticals, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMVP or AIM?
PMV Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. PMV Pharmaceuticals, Inc.'s net income of -$21.1M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, PMV Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PMV Pharmaceuticals, Inc. is -- versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMVPPMV Pharmaceuticals, Inc.-- -- -- -$21.1M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns PMVP or CVM?
CEL-SCI Corp. has a net margin of -- compared to PMV Pharmaceuticals, Inc.'s net margin of --. PMV Pharmaceuticals, Inc.'s return on equity of -51.97% beat CEL-SCI Corp.'s return on equity of -266.61%.
Company Gross Margin Earnings Per Share Invested Capital PMVPPMV Pharmaceuticals, Inc.-- -$0.40 $121.9M CVMCEL-SCI Corp.-- -$1.36 $17M -
What do Analysts Say About PMVP or CVM?
PMV Pharmaceuticals, Inc. has a consensus price target of $7.60, signalling upside risk potential of 512.9%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 765.58%. Given that CEL-SCI Corp. has higher upside potential than PMV Pharmaceuticals, Inc., analysts believe CEL-SCI Corp. is more attractive than PMV Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMVPPMV Pharmaceuticals, Inc.6 0 0 CVMCEL-SCI Corp.1 0 0 -
Is PMVP or CVM More Risky?
PMV Pharmaceuticals, Inc. has a beta of 1.643, which suggesting that the stock is 64.283% more volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock PMVP or CVM?
PMV Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PMV Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMVP or CVM?
PMV Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. PMV Pharmaceuticals, Inc.'s net income of -$21.1M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, PMV Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PMV Pharmaceuticals, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMVPPMV Pharmaceuticals, Inc.-- -- -- -$21.1M CVMCEL-SCI Corp.-- -- -- -$5.7M
-
Which has Higher Returns PMVP or IGC?
IGC Pharma, Inc. has a net margin of -- compared to PMV Pharmaceuticals, Inc.'s net margin of -953.4%. PMV Pharmaceuticals, Inc.'s return on equity of -51.97% beat IGC Pharma, Inc.'s return on equity of -94.42%.
Company Gross Margin Earnings Per Share Invested Capital PMVPPMV Pharmaceuticals, Inc.-- -$0.40 $121.9M IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M -
What do Analysts Say About PMVP or IGC?
PMV Pharmaceuticals, Inc. has a consensus price target of $7.60, signalling upside risk potential of 512.9%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1191.67%. Given that IGC Pharma, Inc. has higher upside potential than PMV Pharmaceuticals, Inc., analysts believe IGC Pharma, Inc. is more attractive than PMV Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMVPPMV Pharmaceuticals, Inc.6 0 0 IGCIGC Pharma, Inc.2 0 0 -
Is PMVP or IGC More Risky?
PMV Pharmaceuticals, Inc. has a beta of 1.643, which suggesting that the stock is 64.283% more volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.
-
Which is a Better Dividend Stock PMVP or IGC?
PMV Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PMV Pharmaceuticals, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMVP or IGC?
PMV Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. PMV Pharmaceuticals, Inc.'s net income of -$21.1M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, PMV Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PMV Pharmaceuticals, Inc. is -- versus 22.51x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMVPPMV Pharmaceuticals, Inc.-- -- -- -$21.1M IGCIGC Pharma, Inc.22.51x -- $191K -$1.8M
-
Which has Higher Returns PMVP or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to PMV Pharmaceuticals, Inc.'s net margin of -255.85%. PMV Pharmaceuticals, Inc.'s return on equity of -51.97% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital PMVPPMV Pharmaceuticals, Inc.-- -$0.40 $121.9M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About PMVP or NBY?
PMV Pharmaceuticals, Inc. has a consensus price target of $7.60, signalling upside risk potential of 512.9%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -83.96%. Given that PMV Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe PMV Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMVPPMV Pharmaceuticals, Inc.6 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is PMVP or NBY More Risky?
PMV Pharmaceuticals, Inc. has a beta of 1.643, which suggesting that the stock is 64.283% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock PMVP or NBY?
PMV Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. PMV Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMVP or NBY?
PMV Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. PMV Pharmaceuticals, Inc.'s net income of -$21.1M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, PMV Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PMV Pharmaceuticals, Inc. is -- versus 10.30x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMVPPMV Pharmaceuticals, Inc.-- -- -- -$21.1M NBYNovaBay Pharmaceuticals, Inc.10.30x 8.90x $521K -$1.3M
-
Which has Higher Returns PMVP or PBYI?
Puma Biotechnology, Inc. has a net margin of -- compared to PMV Pharmaceuticals, Inc.'s net margin of 16.24%. PMV Pharmaceuticals, Inc.'s return on equity of -51.97% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.
Company Gross Margin Earnings Per Share Invested Capital PMVPPMV Pharmaceuticals, Inc.-- -$0.40 $121.9M PBYIPuma Biotechnology, Inc.77.65% $0.17 $156.3M -
What do Analysts Say About PMVP or PBYI?
PMV Pharmaceuticals, Inc. has a consensus price target of $7.60, signalling upside risk potential of 512.9%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $3.50 which suggests that it could fall by -37.83%. Given that PMV Pharmaceuticals, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe PMV Pharmaceuticals, Inc. is more attractive than Puma Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PMVPPMV Pharmaceuticals, Inc.6 0 0 PBYIPuma Biotechnology, Inc.0 1 0 -
Is PMVP or PBYI More Risky?
PMV Pharmaceuticals, Inc. has a beta of 1.643, which suggesting that the stock is 64.283% more volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.656%.
-
Which is a Better Dividend Stock PMVP or PBYI?
PMV Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PMV Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PMVP or PBYI?
PMV Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. PMV Pharmaceuticals, Inc.'s net income of -$21.1M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, PMV Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Puma Biotechnology, Inc.'s PE ratio is 7.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PMV Pharmaceuticals, Inc. is -- versus 1.33x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PMVPPMV Pharmaceuticals, Inc.-- -- -- -$21.1M PBYIPuma Biotechnology, Inc.1.33x 7.60x $54.5M $8.8M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
